Clinical Trial News and Research

RSS

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Laser therapy offers new hope for inoperable pancreatic tumors

UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, phase 1 clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer free.

10 Sep 2026

Aging brain actively shapes biology and progression of tumors

Brain tumors develop within an organ that changes substantially with age. A new review in Ageing and Cancer Research & Treatment examines evidence that the aging brain microenvironment may influence brain tumor progression, treatment resistance, and cognitive outcomes.

10 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

New blood screening algorithm reduces unnecessary Alzheimer's PET scans

A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research from scientists at the Keck School of Medicine of USC published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

9 Sep 2026

Digital program reduces burnout and anxiety in distressed nurses

Burnout, depression, anxiety, and suicide are increasing in the nursing and overall health care workforce, which adversely impacts health care quality and safety.

9 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026

Cognitive behavioral therapy for insomnia may slow biological aging in older adults

A new UCLA Health study found that treatment of insomnia using cognitive behavioral therapy slowed the pace of biological aging in older adults.

8 Sep 2026

Hormone therapy during menopause transition associated with lower heart disease risk

A study led by Virginia Commonwealth University and the University of Pittsburgh provides pivotal insights into one of the most debated questions in women's health: how does hormone therapy for menopause symptoms affect cardiovascular disease risk when used in peri- or early postmenopause?

8 Sep 2026

High-dose flu vaccine protects older adults with lung disease

The risk of being hospitalized for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined results of two large clinical trials presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

8 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Atherosclerosis qualifies as an autoimmune disease

A new study in mice and patients shows that atherosclerosis meets the criteria for an autoimmune disease.

7 Sep 2026

Laughter therapy eases breathlessness in people with COPD

A clinical trial for patients with chronic obstructive pulmonary disease (COPD) shows that laughter therapy can reduce breathing difficulties and is as effective as more traditional breathing exercises. The research is presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

6 Sep 2026

Psilocybin study explores new treatment for cocaine use disorder

Albert Arias, MD, chief of addiction psychiatry at Carilion Clinic, has received an award from the National Institute on Drug Abuse (NIDA) to research how psilocybin, a psychedelic compound being studied for several psychiatric and substance use disorders, can offer a new approach for people with cocaine use disorder.

4 Sep 2026

Prednisone may impair bone health in children with Duchenne muscular dystrophy

In a new study published in Scientific Reports, an international and multidisciplinary research team including Binghamton University researchers identified a set of blood proteins that may explain why the corticosteroid prednisone, although beneficial in treating Duchenne muscular dystrophy (DMD), can interfere with childhood growth and bone health.

4 Sep 2026